Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-Barré Syndrome

Abstract After prompt diagnosis, severe myasthenia gravis and Guillain-Barré syndrome (GBS) usually require management in the intensive care unit. In the myasthenic patient, recognition of precipitating factors is paramount, and frequent monitoring of bulbar, upper airway, and/or respiratory muscle strength is needed to identify impending myasthenic crisis. Noninvasive ventilation can be attempted prior to intubation and mechanical ventilation in the setting of respiratory failure. Cholinesterase inhibitors should be discontinued, but resumed prior to extubation, and steroid dosage could be increased once the airway is secured. In GBS, hemodynamic and respiratory monitoring are essential; however, respiratory failure can develop rapidly and intubation with mechanical ventilation is often required and can be prolonged. Guillain-Barré syndrome can also be complicated by dysautonomia necessitating specific therapies. Prompt recognition and initiation of immunotherapy including intravenous immunoglobulin or plasmapheresis, together with supportive care including treatment of underlying infections and physical therapy, can improve outcomes in both myasthenic crisis and GBS.

[1]  M. Freimer Faculty Opinions recommendation of International consensus guidance for management of myasthenia gravis: Executive summary. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  Emmanuel Fournier,et al.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study , 2016, The Lancet.

[3]  J. Finsterer,et al.  Stress from myasthenic crisis triggers Takotsubo (broken heart) syndrome. , 2016, International journal of cardiology.

[4]  J. Fernández,et al.  Myasthenic Crisis in an Elderly Patient with Positive Antibodies against Acetylcholine and Anti-MuSK, Successfully Treated with Noninvasive Mechanical Ventilation , 2015, Case reports in critical care.

[5]  A. Rabinstein Acute neuromuscular respiratory failure , 2015, Journal of the Neurological Sciences.

[6]  A. Rabinstein,et al.  Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome? , 2015, Arquivos de neuro-psiquiatria.

[7]  I. Jericó,et al.  Myasthenia gravis: descriptive analysis of life‐threatening events in a recent nationwide registry , 2015, European journal of neurology.

[8]  B. Demaerschalk,et al.  IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence? A Critically Appraised Topic , 2015, The neurologist.

[9]  A. Berkowitz,et al.  Posterior reversible encephalopathy syndrome in Guillain-Barré syndrome , 2015, Journal of Clinical Neuroscience.

[10]  E. McNicol,et al.  Pharmacological treatment for pain in Guillain-Barré syndrome. , 2015, The Cochrane database of systematic reviews.

[11]  J. Lünemann,et al.  Intravenous immunoglobulin in neurology—mode of action and clinical efficacy , 2015, Nature Reviews Neurology.

[12]  G. Cutter,et al.  Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? , 2014, Muscle & nerve.

[13]  A. Engeland,et al.  Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries , 2014, Acta neurologica Scandinavica. Supplementum.

[14]  Kangding Liu,et al.  Predictors of outcome of myasthenic crisis , 2014, Neurological Sciences.

[15]  H. Ebadi,et al.  Safety of plasma exchange therapy in patients with myasthenia gravis , 2013, Muscle & nerve.

[16]  M. Uchino,et al.  Myasthenic crisis patients who require intensive care unit management , 2012, Muscle & nerve.

[17]  A. Uncini,et al.  Outcome and its predictors in Guillain–Barré syndrome , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  D. Orlikowski,et al.  Vital Capacity Versus Maximal Inspiratory Pressure in Patients with Guillain–Barré Syndrome and Myasthenia Gravis , 2012, Neurocritical Care.

[19]  Vibhav Bansal,et al.  Broken heart syndrome in myasthenia gravis , 2011, Muscle & nerve.

[20]  R. Holloway,et al.  Plasma Exchange versus Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison Study , 2011, Journal of clinical neuromuscular disease.

[21]  D. Sanders,et al.  Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts , 2011, Muscle & nerve.

[22]  V. Bril,et al.  Comparison of IVIg and PLEX in patients with myasthenia gravis , 2011, Neurology.

[23]  Hester F. Lingsma,et al.  Early recognition of poor prognosis in Guillain-Barré syndrome , 2011, Neurology.

[24]  M. Musthafa,et al.  Guillain-Barré syndrome and SIADH , 2011, Neurology.

[25]  Hester F. Lingsma,et al.  Prediction of respiratory insufficiency in Guillain‐Barré syndrome , 2010, Annals of neurology.

[26]  A. McGrogan,et al.  The Incidence of Myasthenia Gravis: A Systematic Literature Review , 2010, Neuroepidemiology.

[27]  N. Gilhus,et al.  Guidelines for treatment of autoimmune neuromuscular transmission disorders , 2006, European journal of neurology.

[28]  M. Benatar Pearls: myasthenia. , 2010, Seminars in neurology.

[29]  A. Alshekhlee,et al.  Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals , 2009, Neurology.

[30]  Pan‐Chyr Yang,et al.  The Role of Non-invasive Ventilation and Factors Predicting Extubation Outcome in Myasthenic Crisis , 2009, Neurocritical care.

[31]  A. McGrogan,et al.  The Epidemiology of Guillain-Barré Syndrome Worldwide , 2008, Neuroepidemiology.

[32]  E. Wijdicks,et al.  Noninvasive ventilation in myasthenic crisis. , 2008, Archives of neurology.

[33]  C. Bai,et al.  MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis , 2007, Journal of the Neurological Sciences.

[34]  D. Annane,et al.  Immunotherapy for Guillain-Barré syndrome: a systematic review. , 2007, Brain : a journal of neurology.

[35]  E. Steyerberg,et al.  A clinical prognostic scoring system for Guillain-Barré syndrome , 2007, The Lancet Neurology.

[36]  E. Wijdicks,et al.  Mechanical ventilation in patients with Guillain-Barré syndrome. , 2006, Respiratory care.

[37]  N. Gilhus,et al.  Guidelines for the treatment of autoimmune neuromuscular transmission disorders , 2006, European journal of neurology.

[38]  A. Malhotra,et al.  Factors predicting extubation success in patients with Guillain-Barré syndrome , 2006, Neurocritical care.

[39]  H. Diener,et al.  Long-term outcome of Guillain-Barré syndrome , 2006, Neurocritical care.

[40]  R. Hughes,et al.  Intravenous immunoglobulin for Guillain-Barré syndrome. , 2006, The Cochrane database of systematic reviews.

[41]  R. Agarwal,et al.  Noninvasive ventilation in acute neuromuscular respiratory failure due to myasthenic crisis: case report and review of literature , 2005, Emergency Medicine Journal.

[42]  D. Orlikowski,et al.  Significance of phrenic nerve electrophysiological abnormalities in Guillain–Barré syndrome , 2005, Neurology.

[43]  F. Bolgert,et al.  Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. , 2005, Archives of neurology.

[44]  Richard J Barohn,et al.  Supportive care for patients with Guillain-Barré syndrome. , 2005, Archives of neurology.

[45]  Abhishek Kumar,et al.  The Comparative Evaluation of Gabapentin and Carbamazepine for Pain Management in Guillain-Barré Syndrome Patients in the Intensive Care Unit , 2005, Anesthesia and analgesia.

[46]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[47]  M. Mori,et al.  Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[48]  J. Chevrolet,et al.  The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis , 1995, Intensive Care Medicine.

[49]  A. Rabinstein,et al.  Risk of extubation failure in patients with myasthenic crisis , 2005, Neurocritical care.

[50]  A. Moayyeri,et al.  Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience , 2004, BMC neurology.

[51]  R. Schnaar,et al.  Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. , 2004, Brain : a journal of neurology.

[52]  I. Kanazawa,et al.  Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barré syndrome , 2004, Neurology.

[53]  V. Juel Myasthenia gravis: management of myasthenic crisis and perioperative care. , 2004, Seminars in neurology.

[54]  D. Orlikowski,et al.  Respiratory dysfunction in guillain-barré syndrome , 2004, Neurocritical care.

[55]  A. Qureshi,et al.  Myasthenic crisis , 2004, Current treatment options in neurology.

[56]  H. Willison,et al.  Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. , 2003, Brain : a journal of neurology.

[57]  P. Tonali,et al.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. , 2003, Brain : a journal of neurology.

[58]  M. Mori,et al.  Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes , 2003, Neurology.

[59]  A. Vincent,et al.  Clinical aspects of MuSK antibody positive seronegative MG , 2003, Neurology.

[60]  S. Chevret,et al.  Early predictors of mechanical ventilation in Guillain-Barré syndrome , 2003, Critical care medicine.

[61]  S. Chevret,et al.  Intravenous immunoglobulin for myasthenia gravis. , 2003, The Cochrane database of systematic reviews.

[62]  E. Wijdicks,et al.  BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation , 2002, Neurology.

[63]  D. Sanders,et al.  On the Concept of Myasthenic Crisis , 2002, Journal of clinical neuromuscular disease.

[64]  J. Keesey,et al.  “Crisis” in myasthenia gravis: An historical perspective , 2002, Muscle & nerve.

[65]  S. Chevret,et al.  Plasma exchange for myasthenia gravis. , 2002, The Cochrane database of systematic reviews.

[66]  S. Vorstrup,et al.  Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. , 2001, Artificial organs.

[67]  M. Camilleri,et al.  Adynamic ileus in severe Guillain–Barré syndrome , 2001, Muscle & nerve.

[68]  E. Wijdicks,et al.  Anticipating mechanical ventilation in Guillain-Barré syndrome. , 2001, Archives of neurology.

[69]  H. Hartung,et al.  Preceding infections, immune factors, and outcome in Guillain–Barré syndrome , 2001, Neurology.

[70]  P. Tonali,et al.  Therapeutic apheresis in myasthenia gravis. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[71]  G. Pfeiffer,et al.  Indicators of dysautonomia in severe Guillain-Barré syndrome , 1999, Journal of Neurology.

[72]  J. Ulatowski,et al.  Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis , 1999, Neurology.

[73]  R. Hughes,et al.  The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. , 1998, Brain : a journal of neurology.

[74]  E. Wijdicks,et al.  Respiratory management in acute neurologic illness , 1998, Neurology.

[75]  H. Kwiecinski [Disorders of neuromuscular transmission]. , 1998, Neurologia i neurochirurgia polska.

[76]  I. Wirguin,et al.  Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome , 1997, The Lancet.

[77]  S. Chevret,et al.  Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravis , 1997 .

[78]  B. Pentland,et al.  Pain in the Guillain-Barré syndrome: a clinical review , 1994, Pain.

[79]  D. Zochodne Autonomic involvement in Guillain–Barre syndrome: A review , 1994, Muscle & nerve.

[80]  G. Mckhann,et al.  Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China , 1991, The Lancet.

[81]  D. Cornblath,et al.  Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.

[82]  R. Hughes,et al.  A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[83]  G. Mckhann,et al.  Motor conduction studies in guillain‐barré syndrome: Description and prognostic value , 1988, Annals of neurology.

[84]  D. Grob,et al.  The Course of Myasthenia Gravis and Therapies Affecting Outcome a , 1987, Annals of the New York Academy of Sciences.

[85]  K. A. McCarter Plasma Exchange in Guillain-Barré Syndrome , 1982, Nursing times.

[86]  D. Younger,et al.  ASPECTS OF THE NATURAL HISTORY OF MYASTHENIA GRAVIS: CRISIS AND DEATH , 1981, Annals of the New York Academy of Sciences.

[87]  N. Murray,et al.  The sural sensory action potential in Guillain-Barré syndrome. , 1980, Muscle & nerve.

[88]  R. Hughes,et al.  CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.

[89]  D. Elmqvist Myasthenia Gravis , 1975, The Lancet.

[90]  M. Fisher An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). , 1956, The New England journal of medicine.